Galectin Therapeutics
GALT
52 hedge funds and large institutions have $9.77M invested in Galectin Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
29% more call options, than puts
Call options by funds: $866K | Put options by funds: $672K
17% more capital invested
Capital invested by funds: $8.34M → $9.77M (+$1.43M)
16% more funds holding
Funds holding: 45 → 52 (+7)
0.83% more ownership
Funds ownership: 10.65% → 11.48% (+0.83%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$357K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$230K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$227K |
| 4 |
BlackRock
New York
|
+$196K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$349K |
| 2 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$165K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$57K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$35K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$8 | +3 | New |
|
52
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$266 | +100 | +5,000% |
|
|
SIC
53
Salem Investment Counselors
Winston Salem,
North Carolina
| – | +$445 | +167 | New |
|
GALT Hedge Fund Activity: Q2 2017 in Review
52 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2017, worth a combined $9.77M — up 17% from $8.34M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GALT positions and 3 closed out — a net gain of 7 holders — while 13 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $357K. The largest seller was Charles Schwab, cutting an estimated $349K.
- 52 institutional investors held Galectin Therapeutics (GALT) as of Q2 2017, up from 45 in Q1 2017.
- Funds reported $9.77M of Galectin Therapeutics stock for Q2 2017, up 17% quarter-over-quarter.
- 10 funds opened new Galectin Therapeutics positions in Q2 2017 and 3 closed out, a net change of +7 holders.
- The largest Galectin Therapeutics buyer in Q2 2017 was Vanguard Group, an estimated $357K added.
- The largest Galectin Therapeutics seller in Q2 2017 was Charles Schwab, an estimated $349K sold.
Based on aggregated 13F filings for Q2 2017.